Date:8/14/2012

ding the manufacture of clinical trial material, the conduct of clinical studies and preparation of regulatory submissions related to product approval, and that such third parties may fail to perform as expected; and other risks and uncertainties more fully described in ADVENTRX's press releases and periodic filings with the Securities and Exchange Commission. ADVENTRX's public filings with the Securities and Exchange Commission are available at www.sec.gov.

You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date when made. ADVENTRX does not intend to revise or update any forward-looking statement set forth in this press release to reflect events or circumstances arising after the date hereof, except as may be required by law.

(Logo: http://photos.prnewswire.com/prnh/20120612/LA22456LOGO-a)

'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc. Copyright©2012 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. ADVENTRX Pharmaceuticals to Present at 1st Annual Sickle Cell Disease Therapeutics Conference
2. ADVENTRX Applauds Inclusion of Rare Diseases Provisions in the FDA Safety and Innovation Act
3. ADVENTRX Pharmaceuticals To Present At The OneMedForum New York 2012 Emerging Company Finance Conference On July 12
4. ADVENTRX Announces Manufacturing Agreement With Patheon to Manufacture ANX-188 Drug Product
5. ADVENTRX Pharmaceuticals To Present At 2012 BIO International Convention Business Forum
6. FDAnews Announces Medical Device Mobile Apps Virtual Conference
7. Dehaier Medical Announces 2012 Second Quarter and Six Month Financial Results
8. Isis Pharmaceuticals Announces Redemption Of 2 5/8% Convertible Subordinated Notes Due 2027
9. WuXi PharmaTech Announces Second-Quarter 2012 Results
10. Varian Medical Systems CEO Timothy E. Guertin Announces Plans to Retire; Board of Directors Names Dow R. Wilson as Successor
11. Comprehensive Care Corporation Announces Profitable Six Month Financial Results